VivoPower PLC
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Tser Fah Chin
- Full Time Employees
- 41
- Sector
- Energy
- Industry
- Solar
- Address
- The Scalpel London GL United Kingdom EC3M 7AF
- IPO Date
- May 27, 2015
- CIK
- 0001681348
- Website
- vivopower.com
- Similar Companies
- Business
- Meridian Bioscience, Inc. is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. The company's core offerings include diagnostic test kits, purified reagents, antibodies, antigens, specialty biologicals, and molecular and immunological reagents used in diagnostic applications. Meridian specializes in products for gastrointestinal and upper respiratory infections, blood lead level testing, parasitology, serology, and fungal disease diagnosis. It also supplies rare reagents and components for life science research, pharmaceutical, and biotech companies across more than 70 countries. Founded in 1976 and headquartered in Cincinnati, Ohio, Meridian serves a diverse customer base including hospitals, reference laboratories, research centers, physician offices, veterinary testing facilities, diagnostics manufacturers, and agri-bio companies. The company’s products are designed to deliver speed, accuracy, and simplicity in diagnostics, often requiring minimal equipment for use outside the human body. In recent developments, Meridian was acquired in a $1.53 billion all-cash transaction by a consortium led by SD Biosensor and SJL Partners, completed in early 2025. This strategic partnership leverages SD Biosensor’s R&D and mass production capabilities alongside Meridian’s U.S. market expertise to accelerate growth in the in vitro diagnostics (IVD) sector. Additionally, Meridian has appointed a new executive leadership team to drive global growth and innovation. The company also recently launched new animal-free immunoassay interference blockers, setting sustainability standards in diagnostic assay development. Meridian continues to expand its life science business through organic growth and acquisitions, including the integration of the Bioline group, which enhances its portfolio with nucleotides, PCR enzymes, and key global operations in the U.K., Germany, and Australia. Meridian Bioscience operates primarily in the medical equipment manufacturing industry, maintaining strong market positions in infectious disease diagnostics and life science research reagents, with a focus on global distribution and strategic innovation in diagnostics and life science materials. All information is current as of late 2025.
VivoPower announces appointment of Group Finance Director
VivoPower Appoints Group Finance Director
Hershey margin recovery expected to begin in Q2, but Jefferies stays on sidelines over volume concerns
VivoPower positions for scarcity of renewable-backed AI compute sites
Uber reportedly in advanced talks to acquire Delivery Hero
Wells Fargo profit jumps as fee income, credit quality beat estimates
AstraZeneca to pay up to $1.5bn for global rights to lung cancer pill
Noble Capital Markets Initiates Equity Research Coverage on VivoPower
Noble Capital Markets Initiates Equity Research Coverage on VivoPower
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
Agenus shares surge as company secures up to $340M to advance colon cancer trial
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
US Research house initiates Solvonis coverage citing differentiated addiction strategy
Nasdaq slides at open as chip stocks sell off after Samsung earnings
Nvidia's Kyber rack delayed to 2028: Tech giant's stumble hands rivals a rare opening
VivoPower eyes potential earnings boost from battery storage at Norway data center
VivoPower Targets Up To USD$4 million Incremental Annualized EBITDA from Battery Energy Storage Integration at Norway Data Center
VivoPower Targets Up To USD$4 million Incremental Annualized EBITDA from Battery Energy Storage Integration at Norway Data Center
Nasdaq starts the week strong, Dow Jones closes above 53,000 for the first time